The first antibiotic against tuberculosis that has been developed in Germany is now ready for clinical testing. BTZ043, as the newly developed drug substance is called, is also effective against multidrug-resistant pathogens which are increasingly challenging successful treatment worldwide. Scientists from the Ludwig-Maximilians-Universität (LMU) Munich and the Leibniz Institute for Natural Product Research and Infection Biology – Hans Knöll Institute (HKI) in Jena are leading this project. The German Center for Infection Research (DZIF) and the InfectControl 2020 consortium are funding a major part of the trials.
The problem of antibiotic resistance has increased sharply over the last decades. Today, we face the challenge of having to manage a growing number of multidrug-resistant pathogens against which only a few antibiotics have remained effective.
In the case of tuberculosis, the situation is particularly difficult as the treatment regimen still includes several antibiotics which need to be taken simultaneously. Additionally, mycobacteria, which cause tuberculosis, have many mechanisms with which they protect themselves against specific effects of different antibiotics. Consequently, several new agents, ideally with different modes of action, are urgently needed to develop new treatment forms.
New site on mycobacteria targeted
BTZ043 is the first member of a newly discovered class of antibiotics and chemically belongs to the benzothiazinones. “The agent irreversibly binds to an enzyme that is needed for bacterial cell wall synthesis,” explains Dr Florian Kloß, Head of the Transfer Group Antiinfectives of InfectControl 2020 at the HKI.
“As the enzyme can then no longer function, holes develop in the mycobacterial cell walls and the cell contents drain out,” adds DZIF scientist Prof Michael Hoelscher, Director of the Department of Infectious Diseases and Tropical Medicine at the LMU Munich (also see image). “The agent targets tuberculosis bacteria highly selectively and consequently does not affect other bacteria.”
Clinical trial tests tolerance
Recruitment of the first trial subjects for clinical testing of BTZ043 can now be initiated, following the approval of the Federal Institute for Drugs and Medical Devices (BfArM) and the Bavarian Chamber of Physicians’ Ethics Committee.
Led by Prof Hoelscher, up to 40 volunteers will receive the antibiotic at the trial centre of the company Nuvisan in Neu-Ulm. Hoelscher explains the procedure, “We want to ensure that the drug is absorbed by the body and is well-tolerated. To this end, a very low single dose will be administered, and subsequently this dose will gradually be increased for the next trial volunteers.” The aim of the trial is to reach the dose which showed good efficacy in animal models. This dose is far below the highest dose that the animals still tolerated well.
United against infections
A team of scientists and businessmen is involved in the development of this new tuberculosis drug. The agent, BTZ043, was discovered at the HKI in Jena. Since 2014, the drug has been developed further at the DZIF and InfectControl 2020 and other sites in a collaboration project between the Medical Center of the LMU Munich and the HKI.
The HKI is responsible for precise investigations of absorption, distribution, metabolism and excretion as well as for developing analytical methods for detecting metabolites. As a funder, the LMU Munich’s Medical Center is responsible for preclinical and clinical development as well as for quality and safety of the drug. The substance will be produced at Hapila GmbH, a medium-size pharmaceutical company in Gera.
Financing the drug development costs of several million euros has been made possible though joint public and private funding. Particularly the two research alliances DZIF and InfectControl 2020 are involved in developing the active agent. They are being funded by the Federal Ministry of Education and Research.
Prof Michael Hoelscher
Department of Infectious Diseases and Tropical Medicine at the Medical Center of LMU Munich
T +49 89 2180 17613
DZIF Press Office
Karola Neubert and Janna Schmidt
T +49 531 6181 1170/1154
Karola Neubert | idw - Informationsdienst Wissenschaft
Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn
Foods of the future
15.08.2018 | Georg-August-Universität Göttingen
There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.
The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...
New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference
Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...
Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...
Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.
When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...
Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.
Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....
17.08.2018 | Event News
08.08.2018 | Event News
27.07.2018 | Event News
20.08.2018 | Information Technology
20.08.2018 | Life Sciences
20.08.2018 | Information Technology